Research location
Harbin
China
Advertisement
Research activity in Harbin
ChinaCureCurrent currently publishes aggregate city-level research activity for this location: 226 trials and 231 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Harbin
226 linked trials · page 2 of 5Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180 · 1983-01-01 · 1 site observation
RECRUITING
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861 · 2026-12-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)NCT07843940 · 2026-10-05 · 1 site observation
NOT_YET_RECRUITING
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery StenosisNCT07566065 · 2026-04-30 · 1 site observation
NOT_YET_RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · 2025-09-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCNCT07376629 · 2025-08-14 · 1 site observation
ENROLLING_BY_INVITATION
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · 2025-05-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · 2025-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · 2025-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)NCT06921486 · 2025-03-31 · 1 site observation
ACTIVE_NOT_RECRUITING
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerNCT06616532 · 2024-11-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsNCT06644768 · 2024-10-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · 2024-10-22 · 1 site observation
COMPLETED
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447 · 2024-09-26 · 1 site observation
ACTIVE_NOT_RECRUITING
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusNCT06481085 · 2024-06-27 · 1 site observation
COMPLETED
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06448312 · 2024-06-07 · 2 site observations
ACTIVE_NOT_RECRUITING
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With MetforminNCT06415773 · 2024-06-04 · 1 site observation
COMPLETED
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsNCT06194448 · 2024-04-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In ChinaNCT06422663 · 2024-03-22 · 1 site observation
COMPLETED
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsNCT06271837 · 2024-02-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · 2024-02-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · 2024-02-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightNCT06214741 · 2024-02-06 · 1 site observation
COMPLETED
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisNCT06141486 · 2023-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473 · 2023-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 · 2023-11-27 · 1 site observation
COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 · 2023-11-25 · 1 site observation
COMPLETED
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)NCT06122961 · 2023-11-23 · 1 site observation
COMPLETED
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With MetforminNCT06353347 · 2023-11-13 · 1 site observation
COMPLETED
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728 · 2023-11-09 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic PainNCT05838755 · 2023-09-20 · 1 site observation
TERMINATED
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast CancerNCT05945927 · 2023-09-13 · 1 site observation
COMPLETED
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With SurgeryNCT05872763 · 2023-08-11 · 1 site observation
COMPLETED
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · 2023-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCNCT05844150 · 2023-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Ultrasound Ablation for Essential Hypertension（FIM）NCT05795829 · 2023-01-16 · 1 site observation
UNKNOWN
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)NCT05668988 · 2022-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903NCT06846099 · 2022-12-07 · 1 site observation
COMPLETED
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789 · 2022-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669 · 2022-08-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399 · 2022-08-03 · 1 site observation
ACTIVE_NOT_RECRUITING
CARE FOR ALL：an Evaluation of an Asthma QIPNCT05440097 · 2022-07-29 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.